Perimenopause causes hair loss in many women, making it one of the more distressing — yet frequently overlooked — symptoms of this transitional life stage. As oestrogen and progesterone levels fluctuate and decline during the years leading up to the final menstrual period, hair follicles can become more sensitive to androgens, leading to increased shedding, reduced volume, and finer texture. However, not all hair loss during midlife is hormonal in origin; thyroid disorders, iron deficiency, and other conditions can present similarly. This guide explains the mechanisms behind perimenopausal hair loss, how to distinguish it from other causes, and what treatment and self-care options are available in the UK.

How Perimenopause Affects Hair Growth and Loss

Perimenopause can cause diffuse hair shedding (telogen effluvium) and female pattern hair loss by disrupting the hair growth cycle through hormonal fluctuations, though severity and pattern vary between individuals.

Not sure if this is normal? Chat with one of our pharmacists →

Perimenopause — the transitional phase leading up to the final menstrual period — typically begins in a woman's mid-to-late forties and often lasts around four to eight years, though this varies considerably and can be shorter or longer. During this time, many women notice changes in their hair, including increased shedding, reduced volume, and a finer texture. So, does perimenopause cause hair loss? The short answer is: yes, it can, though the relationship is nuanced and individual.

Hair grows in cycles: the anagen (growth) phase, the catagen (transition) phase, and the telogen (resting/shedding) phase. Hormonal fluctuations during perimenopause may disrupt this cycle, pushing more hairs prematurely into the telogen phase — a process known as telogen effluvium. This results in diffuse shedding across the scalp rather than patchy or localised loss.

Separately, some women experience female pattern hair loss (androgenetic alopecia), which is common in midlife and characterised by widening of the central parting and reduced density at the crown. These two patterns can occur independently or together, and it is important to distinguish between them, as they may respond differently to treatment. Hair loss during perimenopause is a recognised and manageable condition, not an inevitable or permanent outcome for every woman.

Further information: NHS Hair loss (Alopecia) page; Primary Care Dermatology Society (PCDS) Female Pattern Hair Loss guidance; British Association of Dermatologists (BAD) Patient Hub.

Hormonal Changes That Contribute to Thinning Hair

Declining oestrogen and progesterone during perimenopause can increase follicle sensitivity to DHT, causing miniaturisation; stress-related cortisol elevation and thyroid dysfunction may also contribute independently.

Hormonal fluctuations during perimenopause — particularly the erratic and eventual decline of oestrogen and progesterone — may contribute to changes in hair growth, though the precise mechanisms are not fully established and multiple factors, including genetics and androgen sensitivity, are involved. These hormones are thought to support follicle health and prolong the anagen phase; as their levels fluctuate, hair follicles may become relatively more sensitive to androgens (such as testosterone and dihydrotestosterone, or DHT), which are present in small amounts in all women.

DHT can bind to receptors in hair follicles and cause them to miniaturise over time — producing progressively thinner, shorter hairs until the follicle eventually becomes dormant. This androgenic effect underlies female pattern hair loss, though it typically presents as diffuse thinning at the crown rather than the temporal recession more commonly seen in men.

Stress and disrupted sleep — both common during perimenopause — can raise cortisol levels, which may in turn suppress hair growth and contribute to shedding. It is also worth noting that thyroid dysfunction is relatively common in midlife and can independently cause hair loss; it is not inherently a perimenopausal change, but it is important to test for it if clinically indicated, rather than attributing all hair changes to oestrogen alone.

Further information: NHS Menopause overview; British Menopause Society (BMS) clinical resources; PCDS Diffuse Alopecia guidance.

Other Causes of Hair Loss to Rule Out During Perimenopause

Thyroid disorders, iron deficiency, nutritional deficiencies, hyperandrogenism, alopecia areata, scalp conditions, and certain medications can all cause hair loss and should be excluded before attributing shedding to perimenopause alone.

While perimenopause can contribute to hair loss, it is clinically important not to assume that hormonal changes are the sole cause. Several other conditions can present with similar symptoms and should be investigated and excluded.

Key conditions to consider include:

• Thyroid disorders — both hypothyroidism and hyperthyroidism can cause diffuse hair thinning; a blood test (TSH, free T4) can identify these

• Iron deficiency — low ferritin is a common and often overlooked cause of hair shedding in women of perimenopausal age; a full blood count and ferritin level are useful first-line tests

• Nutritional deficiencies — vitamin D deficiency may contribute to poor hair quality; routine testing for zinc or biotin is not generally recommended unless deficiency is clinically suspected. Note that high-dose biotin supplementation can interfere with certain laboratory assays, so it should be disclosed to your GP before blood tests are taken

• Hyperandrogenism — features such as acne, hirsutism, or irregular periods may suggest an underlying endocrine cause (such as polycystic ovary syndrome) warranting further investigation

• Alopecia areata — an autoimmune condition causing patchy hair loss, distinct from hormonal thinning

• Scalp conditions — such as seborrhoeic dermatitis or psoriasis, which can affect follicle health

• Medication side effects — certain drugs, including anticoagulants, antidepressants, antihypertensives (particularly beta-blockers), retinoids, antiepileptics, and chemotherapy agents, are associated with hair loss

A thorough history and targeted blood tests — including a full blood count, ferritin, thyroid function, and vitamin D where indicated — are a reasonable first step. Your GP can help determine whether the hair loss pattern and associated symptoms point towards a perimenopausal cause or an alternative diagnosis requiring separate management.

Further information: PCDS Diffuse Alopecia guidance; NICE CKS Alopecia areata; NHS Hair loss page.

Treatment and Management Options Available in the UK

Topical minoxidil is the primary licensed treatment for female pattern hair loss in the UK; HRT may support hair quality but is not indicated solely for hair loss, and spironolactone is an off-label specialist option for androgen-driven cases.

For women whose hair loss is associated with perimenopausal hormonal changes, several treatment options are available through the NHS and privately in the UK.

Hormone Replacement Therapy (HRT) is recommended by NICE guideline NG23 for the management of perimenopausal and menopausal symptoms where appropriate, following an informed discussion of benefits and risks. Some women report improvement in hair quality whilst taking HRT, but the evidence that HRT directly treats hair loss is limited and variable; it is not prescribed solely for this purpose. The MHRA has issued guidance on the risks associated with HRT, including a small increased risk of breast cancer with combined (oestrogen–progestogen) preparations and venous thromboembolism with oral formulations; these risks should be discussed with a GP or menopause specialist as part of shared decision-making. HRT is available in various forms — patches, gels, tablets, and sprays.

Topical minoxidil is a licensed treatment for female pattern hair loss in the UK. Its mechanism is not fully understood but is thought to involve prolonging the anagen phase and enlarging hair follicles; a vasodilatory effect may also play a role. It requires consistent, long-term use and results may take three to six months to become apparent. Important points to be aware of include: an initial increase in shedding during the first few weeks of use (which is temporary), possible scalp irritation or unwanted facial hair growth (hypertrichosis), and the need for indefinite use to maintain any benefit — hair loss typically resumes if treatment is stopped. Topical minoxidil should not be used during pregnancy or breastfeeding. Refer to the product's patient information leaflet (available via the Electronic Medicines Compendium, emc.medicines.org.uk) for full prescribing information.

For women in whom androgens are a significant factor, a GP or dermatologist may consider spironolactone as an off-label option. This requires specialist initiation and is not suitable for women who may become pregnant, as it carries a risk of feminisation of a male foetus; effective contraception is therefore essential throughout treatment. Baseline and periodic monitoring of blood pressure, renal function, and serum potassium is required. Caution is needed in women taking ACE inhibitors, angiotensin receptor blockers, or other potassium-sparing agents. Common adverse effects include menstrual irregularity, breast tenderness, and dizziness. Refer to the BNF for full prescribing guidance.

Experiencing these side effects? Our pharmacists can help you navigate them →

Referral to a consultant dermatologist may be appropriate for complex or persistent cases. Platelet-rich plasma (PRP) injections and low-level laser therapy (LLLT) are sometimes discussed in specialist settings; however, the evidence base for both is currently limited and of variable quality, and these treatments are not routinely commissioned by the NHS — they are mainly available privately. They should not be considered first-line options.

Reporting side effects: If you experience a suspected side effect from any medicine used for hair loss, you can report it to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.

Further information: NICE NG23 Menopause: diagnosis and management; MHRA Drug Safety Update (2019) on HRT and breast cancer risk; Electronic Medicines Compendium (EMC) SmPC for topical minoxidil; BNF: Spironolactone; PCDS Female Pattern Hair Loss guidance.

When to Seek Advice from Your GP or a Specialist

Consult your GP promptly if hair loss is sudden, patchy, accompanied by systemic symptoms, or involves scalp changes such as redness or scarring, as some causes require urgent treatment to prevent permanent damage.

Hair loss can feel deeply personal and affect self-esteem and mental wellbeing significantly. Knowing when to seek professional advice is important both for accurate diagnosis and timely treatment.

You should contact your GP if you notice:

• Sudden or rapid hair shedding over a short period

• Patchy or localised hair loss rather than diffuse thinning

• Hair loss accompanied by other symptoms such as fatigue, weight changes, palpitations, or skin changes — which may suggest a thyroid or other systemic condition

• Scalp changes including redness, scaling, itching, pain, tenderness, pustules, or scarring — these may indicate a scarring alopecia, which requires prompt assessment to prevent permanent follicle damage

• Hair loss that is causing significant psychological distress

• No improvement after several months of self-managed treatment

Your GP can arrange initial blood tests and, if needed, refer you to a dermatologist (for scalp and follicle assessment and treatment) or a menopause specialist if HRT or hormonal management is being considered. NHS menopause clinics are available in many areas, and the British Menopause Society (BMS) maintains a directory of accredited menopause specialists.

Some people also consult a trichologist (a specialist in hair and scalp health). It is important to be aware that the title of trichologist is not a protected or regulated professional title in the UK; trichologists are not medical practitioners and cannot prescribe treatments. If you choose to see a trichologist, check their training and registration (for example, with the Institute of Trichologists or the Trichological Society), and ensure that any underlying medical causes have first been assessed by your GP or a dermatologist.

Early assessment is always preferable, as some causes of hair loss — particularly scarring alopecias — can result in permanent follicle damage if left untreated.

Further information: NHS Hair loss: When to see a GP; PCDS Scarring Alopecia guidance; BAD Patient Hub.

Lifestyle and Self-Care Tips to Support Hair Health

Adequate protein and iron intake, avoiding crash diets, gentle hair care, stress management, and regular physical activity can reduce additional stressors on hair follicles and support overall wellbeing during perimenopause.

Alongside medical treatment, a number of evidence-informed lifestyle measures can help support hair health during perimenopause. While these will not reverse significant hormonal hair loss on their own, they can reduce additional stressors on the hair follicle and support overall wellbeing.

Nutrition plays a central role:

• Ensure adequate intake of protein (hair is primarily made of keratin, a protein), found in eggs, legumes, fish, and lean meat

• Include iron-rich foods such as leafy greens, lentils, and red meat, particularly if blood tests suggest low ferritin

• The NHS advises that most people in the UK should consider taking 10 micrograms (400 IU) of vitamin D daily during autumn and winter; people at higher risk of deficiency (including those who are housebound, have darker skin, or cover most of their skin) are advised to supplement year-round

• Avoid crash dieting or very low-calorie diets, which can trigger telogen effluvium

Hair care habits may also help:

• Use gentle shampoos and avoid excessive heat styling

• Allow hair to dry naturally where possible and minimise tight hairstyles that place traction on follicles

• Scalp massage is a low-risk self-care measure that some people find helpful; evidence for its benefit is limited, but it is unlikely to cause harm

Stress management is particularly relevant during perimenopause. Practices such as yoga, mindfulness, regular physical activity, and adequate sleep can help manage stress, which may in turn reduce stress-related hair shedding. The UK Chief Medical Officers' guidelines recommend at least 150 minutes of moderate-intensity physical activity per week; regular exercise is associated with well-established benefits for sleep quality, mood, cardiovascular health, and bone health during this life stage. Small, consistent changes across these areas can make a meaningful difference to both hair health and overall quality of life.

Further information: NHS Vitamin D advice; UK Chief Medical Officers' Physical Activity Guidelines; NHS Hair loss: self-care.

Frequently Asked Questions